期刊
ACTA NEUROLOGICA SCANDINAVICA
卷 110, 期 4, 页码 221-231出版社
WILEY
DOI: 10.1111/j.1600-0404.2004.00338.x
关键词
topiramate; diabetic neuropathy; neuropathic pain
Objectives - To evaluate the efficacy and tolerability of topiramate in patients with painful diabetic polyneuropathy. Materiaols and methods - Patients with moderate to extreme pain (0-4 Categorical Pain Scale score greater than or equal to 2) were randomized to placebo or topiramate (100, 200, or 400 mg/day) in three similar double-blind trials. The primary efficacy analysis was pain reduction from final visit to baseline in the 100-mm Visual Analog Scale (VAS) for the intent-to-treat populations. Results - After 18-22 weeks of double-blind treatment, pain reductions were numerically greater with topiramate in two studies but differences between topiramate and placebo in VAS scores or in the secondary efficacy endpoints did not reach statistical significance in any of the three studies. Across all studies, 24% of topiramate-treated patients and 8% of placebo-treated patients discontinued due to adverse events; groups did not differ in the occurrence of serious adverse events. Conclusion - These studies did not find topiramate to be significantly more effective than placebo in reducing pain scores in patients with painful diabetic polyneuropathy. Several design features may have precluded the studies from having sufficient sensitivity to differentiate effective and ineffective treatments. The study design and results are instructive for other investigators designing future clinical studies in neuropathic pain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据